Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This phase III trial is testing whether an experimental drug called TQB3909 can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) whose disease has returned or stopped responding to prior treatments. Participants will be randomly assigned to re…

This trial is testing an experimental oral medication called TQF3250 in people with type 2 diabetes who are also overweight or obese. The drug is designed to mimic a natural hormone that helps control blood sugar and appetite. The study aims to see if the drug is safe, tolerable,…

This phase II trial evaluates TQB3454, an oral drug that targets a specific genetic mutation (IDH1) found in some solid tumors. The study enrolls adults with advanced solid tumors, including glioma, other IDH1-mutated cancers, and biliary tract cancer without the mutation. Partic…

This study tests whether a new antibiotic called polymyxin E2, given both through a vein and as a mist inhaled into the lungs, can safely cure hospital-acquired pneumonia caused by drug-resistant bacteria. About 48 adults with this serious lung infection will receive either the n…

This trial investigates TQB3126, a drug designed to destroy specific proteins that help breast cancer grow. It involves adults with breast cancer whose disease has worsened after prior treatments. The study will first find the safest dose and then test how well it works, alone or…

This study will test the drug Tabellvi (adalimumab) in 50 Chinese adults with moderate to severe Crohn's disease. The goal is to see how safe and effective it is in real-world settings, focusing on side effects and whether patients achieve remission after 26 weeks. Participants m…

This study tests a new inhaled powder called TQC3927 for people with chronic obstructive pulmonary disease (COPD). The goal is to see if different doses can improve lung function and are safe over a short treatment period. About 90 adults aged 40 to 75 with COPD will take part. T…

This study tests a new drug called TQB2934 in 260 people whose multiple myeloma has returned or stopped responding to treatment. Participants are randomly assigned to receive either TQB2934 or one of several standard treatments chosen by their doctor. The main goal is to see if T…

This study looks at the safety of a drug called adalimumab in 30 Chinese children aged 6 to 17 with moderate-to-severe Crohn's disease. Researchers will track side effects over 12, 26, and 52 weeks of treatment. The goal is to understand how safe the drug is in real-world use for…

This study tests the drug adalimumab in 30 Chinese children aged 4 to 17 with severe plaque psoriasis that hasn't improved with creams or light therapy. The goal is to see if adalimumab can safely reduce skin symptoms like redness and scaling. The main measure is how many childre…

This study tests the safety of an inhaled medication called TQC3721 in 800 people with moderate to severe chronic obstructive pulmonary disease (COPD). Participants must have completed a previous related study. The main goal is to track side effects and lab abnormalities, while a…

This early-stage trial tests a new oral drug called TQB3217 in 40 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. Researchers will also look for any…

This trial tests an experimental oral drug called TQB3201 in people with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug works by breaking down a key protein that fuels cancer growth, even in cancers with resistance mutat…

This Phase 3 trial tests an inhaled drug called TQC3721 in 666 people with moderate-to-severe COPD. The drug works by reducing inflammation and opening airways. Participants will inhale the drug or a placebo daily for up to 24 weeks to see if it improves lung function.

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.